Top Markets
#1 Akedo Akedo +55.87%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +47.84%
#4 Velvet Velvet +37.51%
#5 Black Phoenix Black Phoenix +34.10%
#6 Cross Cross +28.39%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.20%
#8 QANplatform QANplatform +14.28%
#9 Perle Perle +13.52%
#10 OVERTAKE OVERTAKE +13.48%
Coin of the day
Akedo Akedo
설정
언어
한국어
통화
USD
테마
Ovoca Bio plc Ovoca Bio plc

Ovoca Bio plc

OVXA
주식 순위 #38531
Headquartered in Dublin, Ireland, and established in 1985, Ovoca Bio plc... Headquartered in Dublin, Ireland, and established in 1985, Ovoca Bio plc operates as a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market innovative therapies for various female sexual dysfunctions. Its primary drug candidate, BP-101, is being developed as a medical treatment for premenopausal women diagnosed with hypoactive sexual desire disorder. This compound is presently in Phase II clinical investigation in Australia and New Zealand, and has progressed to Phase III clinical trials within Russia. Beyond its core pharmaceutical work, the company also participates in mineral exploration and offers supplementary support services. The organization, originally incorporated as Ovoca Gold plc, rebranded to Ovoca Bio plc in July 2018.
주가
$0.01142111
마지막 동기화: 2025-03-21
시가총액
$930.66K
변동 (1일)
0.18%
변동 (1년)
0.00%
국가
IE
거래 Ovoca Bio plc (OVXA)

카테고리

Healthcare
Ovoca Bio plc (OVXA)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Ovoca Bio plc의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Ovoca Bio plc의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE